Abstract:4445
Despite remarkable responses with imatinib in chronic phase chronic myeloid leukemia (CML-CP), there remains a proportion of patients who are resistant or intolerant to imatinib treatment. Dasatinib is effective second-line treatment for this patient population. Importantly, without effective therapeutic intervention, these patients inevitably progress to advanced phases of disease, have a short survival and declined health outcomes. This emphasizes the importance of patient-reported outcom… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.